LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Washington, DC: American Society for Microbiology, 2002. B. Cefepime 1. Bradley J. The Safety And Efficacy Of Cefepime In Pediatrics—Introduction. Pediatr Infect Dis J. March 2001;20(3):329–330. 2. Kessler RE. Cefepime microbiologic profile and update. Pediatr Infect Dis J. March 2001;20(3):331–336. Prepared for a presentation entitled “NICU Drug Therapy Update” at the AWHONN 2004 Convention, June 28, 2004, Tampa, Fla. From the Sharp Mary Birch Hospital for Women, San Diego, Calif. Corresponding author: Jason Sauberan, PharmD, Sharp Mary Birch Hospital for Women, 3003 Health Center Dr, San Diego, CA 92123 (e-mail: [email protected]). 292 LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 Bibliography 293 3. Blumer JL, Reed MD, Knupp C. Review of the pharmacokinetics of cefepime in children. Pediatr Infect Dis J. March 2001;20(3):337–342. 4. Capparelli EV, Rasmussen M, Bradley JS. Population Pharmacokinetics of Cefepime in Newborn Infants [abstract 2263]. In: Program and abstracts of the 2004 Pedi- atric Academic Societies’ Annual Meeting, San Francisco, CA. C. Caspofungin 1. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspo- fungin in immunocompromised pediatric patients. Pediatr Infect Dis J. 2003 Aug;22(8):747–8. 2. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics of caspofungin in pediatric patients [abstract M-896]. In: Program and abstracts of the 42nd Interscience Con- ference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Washington, DC: American Society for Microbiology, 2002; 395. 3. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifun- gal class. J Antimicrob Chemother. 2003 Mar;51(3):513–21. D. Voriconazole 1. Maples HD, Stowe CD, Saccente SL, Jacobs RF. Voriconazole serum concentrations in an infant treated for trichosporon beigelii infection. Pediatr Infect Dis J. Nov 2003;22(11):1022–24. 2. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21: 240–8. 3. Gothard P, Rogers TR. Voriconazole for serious fungal infections. Int J Clin Pract. 2004 Jan;58(1):74–80. E. Neonatal Candidiasis review: Bliss JM, Wellington M, Gigliotti F. Antifungal pharma- cotherapy for neonatal candidiasis. Semin Perinatol. 2003 Oct;27(5):365–74. F. Meropenem 1. van Enk JG, Touw DJ, Lafeber HN. Pharmacokinetics of meropenem in preterm neonates. Ther Drug Monit. 2001 Jun;23(3):198–201. 2. Bradley JS, Faulkner KL, Klaugman KP.Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J. 1996 Aug;15(8):749–57. 3. Bradley JS. Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr Infect Dis J. 1997 Mar;16(3):263–8. G. Aminoglycosides (gentamicin or tobramycin) 1. de Hoog M, van Zanten BA, Hop WC, Overbosch E, Weisglas-Kuperus N, van den Anker JN. Newborn hearing screening: tobramycin and vancomycin are not risk fac- tors for hearing loss. J Pediatr. 2003 Jan;142(1):41–6. What does the older research say? 2. Knight JA, Davis EM, Manouilov K, Hoie EB. The effect of postnatal age on gentamicin pharmacokinetics in neonates. Pharmacotherapy. 2003 Aug;23(8): 992–6. 3. Avent ML, Kinney JS, Istre GR, Whitfield JM. Gentamicin and tobramycin in neonates: comparison of a new extended dosing interval regimen with a traditional multiple daily dosing regimen. Am J Perinatol. 2002 Nov;19(8):413–20. 4. Young TE. Aminoglycoside Therapy in Neonates. Neoreviews 2002;3:243–248 5. DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy. 2003 Aug;23(5):585–91. LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 294 JOURNAL OF PERINATAL AND NEONATAL NURSING/JULY–SEPTEMBER 2004 H. Vancomycin 1. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, Kildoo C, Connor JD. The influences of renal function and maturation on vancomycin elimi- nation in newborns and infants. J Clin Pharmacol. 2001 Sep;41(9):927–34. 2. Tan WH, Brown N, Kelsall AW, McClure RJ. Dose regimen for vancomycin not need- ing serum peak levels?Arch Dis Child Fetal Neonatal Ed. 2002 Nov;87(3):F214–6. 3. Shackley F, Roberts P, Heath P, et al. Trough-only monitoring of serum vancomycin concentrations in neonates. J Antimicrob Chemother 1998;41:141–2. 4. Struthers S, Underhill H, Albersheim S, Greenberg D, Dobson S. A comparison of two versus one blood culture in the diagnosis and treatment of coagulase- negative staphylococcus in the neonatal intensive care unit. J Perinatol. 2002 Oct- Nov;22(7):547–9. 5. Rubin LG, Sanchez PJ, Siegel J, Levine G, Saiman L, Jarvis WR; Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists’ practices. Pediatrics. 2002 Oct;110(4):e42. 6. Dawson PM. Vancomycin and gentamicin in neonates: hindsight, current controver- sies, and forethought. J Perinat Neonatal Nurs. 2002 Sep;16(2):54–72. Good one for the reference list. I. Rifampin 1. Shama A, Patole SK, Whitehall JS. Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia. Acta Paediatr. 2002;91(6):670–3. 2. Tan TQ, Mason EO Jr, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993 Nov;37(11):2401–6. J. IVIG 1. Mohan PV, Tarnow-Mordi W, Stenson B, Brocklehurst P,Haque K, Cavendish V, Cust A. Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants? Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F5–8. 2. Suri M, Harrison L, Van de Ven C, Cairo MS. Immunotherapy in the prophylaxis and treatment of neonatal sepsis. Curr Opin Pediatr. 2003 Apr;15(2):155–60. 3. INIS, the international neonatal immunotherapy study http://www.npeu.ox. ac.uk/inis/index.php K. Xigris 1. Rawicz M, Sitkowska B, Rudzinska I, Kornacka MK, Bochenski P. Recombinant human activated protein C for severe sepsis in a neonate. Med Sci Monit. 2002 Nov;8(11):CS90–4. L. HIV 1. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Nov 26, 2003. http://www.aidsinfo.nih.gov/guidelines/perinatal/PER 112603.pdf 2. Efficacy of three short-course regimens of zidovudine and lamivudine in prevent- ing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002 Apr 6;359(9313):1178–86. 3. Brocklehurst P, Volmink J Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd. LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 Bibliography 295 4. Short postexposure prophylaxis in newborn babies to reduce mother-to-child trans- mission of HIV-1: NVAZ randomised clinical trial. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, Liomba G, Nkhoma C, Miotti PG, Hoover DR. Lancet. 2003 Oct 11;362(9391):1171–7. 5. Vyankandondera J, Luchters S, Hassink E, et al. Reducing risk of HIV-1 transmis- sion from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study). Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract LB7. a. Crabb C. Breastfeeding and HIV transmission AIDS 2003; 17(17):N13– N14. b. HPTN 023 Study Group. Population Pharmacokinetics of Low Dose Nevirap- ine (NVP) for Prevention of Breast Milk HIV Transmission in Infants from Birth Through 6 Months of Age [abstract 1876]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. 6. AZT. a. Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ.